Clinical trials: Pulmonary Hypertension, Interstitial Lung Disease
Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease
An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The purpose of this study is to provide continued access to TPIP for participants who have successfully completed the open-label extension (OLE) studies of INS1009-203 for PAH or INS1009-212 for PH-ILD.
- Trial name
- NCT06939647
- Testing
- Treprostinil Palmitil
- Sponsor
- Insmed Incorporated
Pulmonary Hypertension Due to Lung Diseases and Hypoxia
LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD).
- Trial name
- NCT05798923
- Testing
- LAM-001
- Where
- 4 sites in United States
- Volunteers
- 85 people
- Sponsor
- IRulya Therapeutics Inc.
Pulmonary Hypertension Due to Lung Disease (Disorder)
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
The purpose of this study is to find out if L606 is safe and if it helps people with high blood pressure in the lungs (pulmonary hypertension) caused by interstitial lung disease (PH-ILD, WHO Group 3).
- Trial name
- Re-Spire (NCT07285655)
- Testing
- L606
- Where
- 44 sites in United States, Australia and 10 more
- Volunteers
- 344 people
- Sponsor
- Liquidia Technologies, Inc.
Pulmonary Hypertension, Interstitial Lung Disease
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.
- Trial name
- PALM-ILD (NCT07179380)
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 186 sites in United States, Argentina and 28 more
- Volunteers
- 344 people
- Sponsor
- Insmed Incorporated
Pulmonary Hypertension, Interstitial Lung Disease (ILD)
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary…
- Trial name
- MOMENTOUS (NCT06911632)
- Testing
- ECG-based AI Device - Results Returned to Investigator, Echocardiogram and Right Heart Catheterization, ECG-based AI Device - Results Not Returned to Investigator
- Where
- 40 sites in United States
- Volunteers
- 900 people
- Sponsor
- Tempus AI
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH).
- Trial name
- ROCSTAR (NCT07175038)
- Testing
- ROC-101
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 40 people
- Sponsor
- AllRock Bio, Inc.
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial
Assessment of Continuous Measurement of Transcutaneous CO2 for Evaluation of Alveolar Dead Space During Exercise
The study aim is to monitor, during exercise tests carried out in various conditions, the alveolar dead space, by means of continuous transcutaneous measurement of Pt CO2, which would be used as a surrogate for arterial PaCO2.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial, Chronic Heart Failure, Pulmonary Arterial Hypertension
- Trial name
- TEASE (NCT03718780)
- Testing
- simultaneous determination of PaCO2 and PtCO2, Hyperventilation test, Exercise test
- Where
- 4 sites in France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Metropole Savoie
Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
Background: Injury or diseases of the heart and lung can sometimes cause scar tissue (fibrosis) to build up in those organs. Current imaging scans can see this scar tissue once it has formed, but researchers want to find a way to…
- Conditions
- Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation, Interstitial Lung Disease, Acute Lung Injury
- Trial name
- NCT07613099
- Testing
- [18F]FAPI-74, 18F-FAPI-74 PET/CT Imaging
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Hypertension, Interstitial Lung Disease
Aerobic Exercise in Patients With Pulmonary Hypertension
This study will determine if a rehabilitation exercise program can help people with pulmonary hypertension (PH) increase their physical activity.
- Trial name
- NCT00678821
- Testing
- Aerobic exercise
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
COPD (Chronic Obstructive Pulmonary Disease), Rehabilitation
Tele-Pulmonary Rehabilitation For Patients With Chronic Lung Diseases
Pulmonary rehabilitation is a key treatment for lung diseases, but many patients struggle to attend sessions due to travel distances, physical limitations, or logistical barriers.
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), Rehabilitation, Bronchiectasis Adult, Pulmonary Arterial Hypertension (PAH)
- Trial name
- TELE-PRIME (NCT07666841)
- Testing
- Tele-Rehabilitation
- Where
- 2 sites in Israel
- Volunteers
- 90 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Interstitial Lung Disease, COPD
Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs
The objective of this registry is to collect and evaluate various clinical effectiveness parameters in patients with transplanted donor lung that were preserved and transported within the LUNGguard system, as well as…
- Conditions
- Interstitial Lung Disease, COPD, Cystic Fibrosis, Pulmonary Fibrosis
- Trial name
- GUARDIANLUNG (NCT04930289)
- Testing
- LungGuard, BAROGuard
- Where
- 15 sites in United States, Belgium
- Volunteers
- 3,500 people
- Sponsor
- Paragonix Technologies
Interstitial Lung Disease, Pulmonary Hypertension
Hyperpolarized Xenon MRI in Adults With Pulmonary Hypertension in Interstitial Lung Disease and Systemic Sclerosis
This study aims to evaluate a noninvasive magnetic resonance imaging technique using hyperpolarized xenon gas to measure lung function in adults with interstitial lung disease, pulmonary hypertension, and systemic sclerosis.
- Conditions
- Interstitial Lung Disease, Pulmonary Hypertension, Systemic Sclerosis
- Trial name
- NCT07821398
- Testing
- Hyperpolarized 129 Xenon Gas
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Bastiaan Driehuys
Pulmonary Hypertension, Interstitial Lung Disease
A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)
A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Mosliciguat in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases, Cardiovascular Diseases
- Trial name
- NCT07816185
- Testing
- Mosliciguat, Dry Powder Inhaler
- Where
- 3 sites in United States
- Volunteers
- 376 people
- Sponsor
- Pulmovant, Inc.
Pulmonary Hypertension, Interstitial Lung Disease
A Study of Mosliciguat in PH-ILD
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung…
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases
- Trial name
- PHocus (NCT06635850)
- Testing
- Mosliciguat, Dry Powder Inhaler
- Where
- 85 sites in United States, Argentina and 18 more
- Volunteers
- 135 people
- Sponsor
- Pulmovant, Inc.
Hypertension, Pulmonary, Lung Diseases, Interstitial
Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
The primary purpose of this study is to assess the effect of TX000045 on pulmonary vascular resistance (PVR) in participants with pulmonary hypertension secondary to interstitial lung disease (PH-ILD) and to assess the safety and…
- Trial name
- NCT07473700
- Testing
- TX000045
- Where
- 16 sites in United States, Poland and 4 more
- Volunteers
- 25 people
- Sponsor
- Tectonic Operating Company, Inc.
Pulmonary Hypertension, Interstitial Lung Disease (ILD)
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a…
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases
- Trial name
- NCT07333183
- Testing
- inhaled mosliciguat, Dry Powder Inhaler
- Where
- 13 sites in United States
- Volunteers
- 20 people
- Sponsor
- Pulmovant, Inc.
Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD).
- Conditions
- Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
- Trial name
- NCT06388421
- Testing
- Prospective study assessments
- Where
- 71 sites in United States, Puerto Rico
- Volunteers
- 900 people
- Sponsor
- United Therapeutics
Systemic Sclerosis, Diffuse Sclerosis Systemic
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment…
- Conditions
- Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
- Trial name
- SSc (NCT03630211)
- Testing
- Cyclophosphamide, Mesna, Rituximab
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Paul Szabolcs
Pulmonary Hypertension, Interstitial Lung Disease
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-311 (NCT07179380).
- Trial name
- NCT07234032
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 9 sites in United States, Japan and 3 more
- Volunteers
- 344 people
- Sponsor
- Insmed Incorporated
Pulmonary Hypertension, Interstitial Lung Disease
The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease
This study evaluates the effects of a structured home exercise program in participants with pulmonary hypertension associated with interstitial lung disease.
- Trial name
- NCT07561034
- Testing
- Home Exercise Program, Aerobic Plus Strength Training, Home Exercise Program, Aerobic Only
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Rochester